Nacelle Therapeutics Inc. commercially develops licensed K-State technologies that exploit the self-assembling properties of small peptides in membrane environments. These new structures offer the potential to enhance drug delivery across barrier membranes as well as treat certain human ailments such as cystic fibrosis and bacterial infections. In collaboration with researchers at both K-State and elsewhere, the company is investigating new clinical and environmental applications.